STA Pharma completes clinical supply of PhoenixMD’s breast cancer treatment

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/kritchanut)
(Image: Getty/kritchanut)

Related tags: STA pharma, WuXi STA, Breast cancer, Clinical trial, Metastatic breast cancer, HER2, Gmp

Clinical trial supply for the first targeted treatment of triple-negative breast cancer completed through PhoenixMD and STA Pharmaceutical agreement.

The drug candidate from Phoenix Molecular Designs, PMD-026, the first RSK inhibitor therapy for triple-negative breast cancer (TNBC), will enter the clinic in an upcoming Phase I/Ib study in women with breast cancer in the third quarter of 2019. The drug will also enter a toxicology study for investigational new drug (IND) application purposes.

STA Pharmaceutical, a subsidiary of WuXI STA, completed the manufacturing of the clinical supply of the drug product after the two companies entered an agreement in March 2018. STA produced a multi-kg drug supply of the candidate under good manufacturing practices (GMP) practices which is sufficient to treat all patients in the clinical trial.

The collaboration, which PhoenixMD said was a critical part of advancing the drug candidate to the clinic, will continue as WuXi STA recently expanded its operations in the US to include capsule production under GMP regulatory compliance.  

According to Sandra Dunn, CEO of PhoenixMD, metastatic TNBC, for which PMD-026 is a treatment, is the most deadly type of breast cancer. She added that PMD-026 is the first drug to ever reach clinical use against this novel target.

As a ribosomal S6 kinase (RSK) inhibitor therapy, PMD-026 works on the kinase protein that drives the growth of the breast cancer subtype relative to the hormone positive or HER-2 positive breast cancer. The company stated that the candidate is also applicable to greater than 14 different types of cancers.

Related news

Show more

Related products

show more

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 15-Aug-2022 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Standardizing data with NCI controlled terminology

Standardizing data with NCI controlled terminology

Formedix | 18-Jul-2022 | Technical / White Paper

The use of consistent terminology within and between studies is critical to enabling an efficient trial process. CDISC standards such as CDASH, SDTM, SEND...

Planning Your First-In-Human Trial

Planning Your First-In-Human Trial

Altasciences | 15-Jul-2022 | Technical / White Paper

A first-in-human (FIH) clinical trial is a significant milestone in the development of a potential new drug. A successfully conducted FIH trial provides...

Related suppliers

Follow us

Products

View more

Webinars